361 related articles for article (PubMed ID: 33562819)
1. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma.
Lah TT; Novak M; Pena Almidon MA; Marinelli O; Žvar Baškovič B; Majc B; Mlinar M; Bošnjak R; Breznik B; Zomer R; Nabissi M
Cells; 2021 Feb; 10(2):. PubMed ID: 33562819
[TBL] [Abstract][Full Text] [Related]
2. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
3. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
Robaina Cabrera CL; Keir-Rudman S; Horniman N; Clarkson N; Page C
Pulm Pharmacol Ther; 2021 Aug; 69():102047. PubMed ID: 34082108
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of
Henshaw FR; Dewsbury LS; Lim CK; Steiner GZ
Cannabis Cannabinoid Res; 2021 Jun; 6(3):177-195. PubMed ID: 33998900
[No Abstract] [Full Text] [Related]
5. In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.
Perez E; Fernandez JR; Fitzgerald C; Rouzard K; Tamura M; Savile C
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056807
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways.
Viereckl MJ; Krutsinger K; Apawu A; Gu J; Cardona B; Barratt D; Han Y
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740979
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of cannabinoids against glioblastoma multiforme: A systematic review.
Kyriakou I; Yarandi N; Polycarpou E
Phytomedicine; 2021 Jul; 88():153533. PubMed ID: 33812759
[TBL] [Abstract][Full Text] [Related]
8. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
[TBL] [Abstract][Full Text] [Related]
9. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure.
Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME
J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780
[TBL] [Abstract][Full Text] [Related]
10. Dose-Related Inhibition of Capsaicin Responses by Cannabinoids CBG, CBD, THC and their Combination in Cultured Sensory Neurons.
Anand U; Oldfield C; Pacchetti B; Anand P; Sodergren MH
J Pain Res; 2021; 14():3603-3614. PubMed ID: 34853533
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.
Hernán Pérez de la Ossa D; Lorente M; Gil-Alegre ME; Torres S; García-Taboada E; Aberturas Mdel R; Molpeceres J; Velasco G; Torres-Suárez AI
PLoS One; 2013; 8(1):e54795. PubMed ID: 23349970
[TBL] [Abstract][Full Text] [Related]
12. The antinociceptive activity and mechanism of action of cannabigerol.
Wen Y; Wang Z; Zhang R; Zhu Y; Lin G; Li R; Zhang J
Biomed Pharmacother; 2023 Feb; 158():114163. PubMed ID: 36916438
[TBL] [Abstract][Full Text] [Related]
13. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
De Petrocellis L; Ligresti A; Moriello AS; Allarà M; Bisogno T; Petrosino S; Stott CG; Di Marzo V
Br J Pharmacol; 2011 Aug; 163(7):1479-94. PubMed ID: 21175579
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
López-Valero I; Torres S; Salazar-Roa M; García-Taboada E; Hernández-Tiedra S; Guzmán M; Sepúlveda JM; Velasco G; Lorente M
Biochem Pharmacol; 2018 Nov; 157():275-284. PubMed ID: 30125556
[TBL] [Abstract][Full Text] [Related]
15. Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol.
Mammana S; Cavalli E; Gugliandolo A; Silvestro S; Pollastro F; Bramanti P; Mazzon E
Medicina (Kaunas); 2019 Nov; 55(11):. PubMed ID: 31752240
[No Abstract] [Full Text] [Related]
16. Cannabinoids in clinical practice.
Williamson EM; Evans FJ
Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the cytotoxicity induced by cannabinoids on human ovarian carcinoma cells.
Sooda K; Allison SJ; Javid FA
Pharmacol Res Perspect; 2023 Dec; 11(6):e01152. PubMed ID: 38100640
[TBL] [Abstract][Full Text] [Related]
18. The Pharmacological Case for Cannabigerol.
Nachnani R; Raup-Konsavage WM; Vrana KE
J Pharmacol Exp Ther; 2021 Feb; 376(2):204-212. PubMed ID: 33168643
[TBL] [Abstract][Full Text] [Related]
19. Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews.
Rock EM; Goodwin JM; Limebeer CL; Breuer A; Pertwee RG; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2011 Jun; 215(3):505-12. PubMed ID: 21243485
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor.
Fischedick J; Van Der Kooy F; Verpoorte R
Chem Pharm Bull (Tokyo); 2010 Feb; 58(2):201-7. PubMed ID: 20118579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
